University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.
Department of Otolaryngology, University of Michigan, Ann Arbor, MI, USA.
Int J Pediatr Otorhinolaryngol. 2023 Dec;175:111767. doi: 10.1016/j.ijporl.2023.111767. Epub 2023 Oct 31.
Fetal goiter is a rare congenital disorder that can present with life-threatening neonatal airway obstruction. Lifesaving and function-preserving airway management strategies are available, but routine delivery affords a limited window for intervention. Accordingly, fetal goiter is reported among the most common indications for ex-utero intrapartum treatment (EXIT). While EXIT prolongs the window for airway intervention to benefit the neonate, it elevates the risk to the pregnant person and requires extensive resources; therefore, data to guide ideal treatment selection are essential. This study aims to compare perinatal airway interventions between individuals with a birth hospitalization discharge diagnosis (BHDD) of goiter and the general population.
Individuals with and without BHDD of goiter were identified in the Healthcare Cost and Utilization Project (HCUP) Kids' Inpatient Database from 2000 to 2019. The frequency of airway interventions on day of life (DOL) 0 or 1 were compared using the Rao-Scott chi-square test. Additionally, gestational age, type of intervention, complications, mortality, birth weight, and length of stay were examined for the goiter cohort.
Two-hundred eighty-seven weighted cases of goiter were identified in the study period. The population was 61 % male, 55 % White, and median birthweight was 3.3 kg. The median length of stay was 4.3 days, and average total charges were $42,332. Airway intervention on DOL 0 or 1 was performed in 16.9 % of individuals with goiter compared to 1.6 % in neonates without goiter (p < 0.001). Interventions in the goiter cohort included endotracheal intubation in 16 % of cases, laryngoscopy/bronchoscopy in 1-5% of cases, and tracheostomy in <1 % of cases. Fewer than 1 % of individuals undergoing intubation additionally had mass decompression/resection on DOL 0 or 1. No neonates received extracorporeal membrane oxygenation cannulation or cardiopulmonary resuscitation. Hypoxic encephalopathy occurred in <1 % of cases, among which endotracheal intubation was the only airway intervention performed. There were no mortalities among neonates with goiter.
Individuals with BHDD of goiter receive significantly higher rates of perinatal airway intervention. In most cases, endoscopic interventions alone were sufficient to avoid hypoxic neurological complications. These findings contribute to data to aid in clinical counseling and empower patients to make informed decisions according to their values and treatment goals.
胎儿甲状腺肿是一种罕见的先天性疾病,可导致新生儿气道阻塞,危及生命。目前已经有挽救生命和保留功能的气道管理策略,但常规分娩提供的干预时间窗口有限。因此,胎儿甲状腺肿是最常见的子宫内分娩治疗(EXIT)适应证之一。虽然 EXIT 延长了为新生儿进行气道干预的时间窗口,但也增加了孕妇的风险,并需要大量资源;因此,指导理想治疗选择的数据至关重要。本研究旨在比较有和无胎儿甲状腺肿出生住院诊断(BHDD)的个体之间围产期气道干预的差异。
从 2000 年至 2019 年,在医疗保健成本和利用项目(HCUP)儿童住院数据库中确定了有和无 BHDD 甲状腺肿的个体。使用 Rao-Scott 卡方检验比较出生后第 0 或 1 天气道干预的频率。此外,还检查了甲状腺肿组的胎龄、干预类型、并发症、死亡率、出生体重和住院时间。
在研究期间,共确定了 287 例有 BHDD 的甲状腺肿病例。人群中男性占 61%,白人占 55%,中位出生体重为 3.3kg。中位住院时间为 4.3 天,平均总费用为 42332 美元。有甲状腺肿的个体在出生后第 0 或 1 天进行气道干预的比例为 16.9%,而无甲状腺肿的新生儿为 1.6%(p<0.001)。甲状腺肿组的干预措施包括气管插管 16%,喉镜/支气管镜检查 1-5%,气管切开术<1%。少于 1%的接受插管的个体在出生后第 0 或 1 天还进行了肿块减压/切除术。没有新生儿接受体外膜肺氧合插管或心肺复苏。缺氧性脑病的发生率<1%,其中气管插管是唯一进行的气道干预。甲状腺肿新生儿无死亡。
有 BHDD 的甲状腺肿个体接受围产期气道干预的比例明显更高。在大多数情况下,仅进行内镜干预就足以避免缺氧性神经并发症。这些发现有助于提供数据,以帮助临床咨询,并使患者能够根据自己的价值观和治疗目标做出明智的决策。